AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31036759 — intervention group
Group type: COMPARATOR
Intervention: AST-120
Number of subjects: 125
Study 31036759 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study 29885163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D along with metformin
Number of subjects: 140
Study 29885163 — intervention group
Group type: COMPARATOR
Intervention: Metformin only
Number of subjects: 140
Study 25231596 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pregnancy urinary metabolomic profile
Number of subjects: 50
Study 24445832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 159
Study 24445832 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes with adenoidectomy
Number of subjects: 159
Study 24445832 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 159
Study 23205751 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 0
Study 23205751 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 0
Study 23205751 — intervention group
Group type: COMPARATOR
Intervention: Combination exercise
Number of subjects: 0
Study 23205751 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 0
Study 19505384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol treatment with thiamphenicol glycinate acetylcysteinate (250 mg/day in 2 administrations) plus beclomethasone (400 microg/day in 2 administrations) for 10 days/month over a period of 6 months.
Number of subjects: 204
Study 19505384 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 204
Study 19505384 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol treatment with thiamphenicol glycinate acetylcysteinate plus beclomethasone.
Number of subjects: 204
Study 17126337 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (300 mg daily for 6 weeks)
Number of subjects: 53
Study 17126337 — intervention group
Group type: COMPARATOR
Intervention: Oral dydrogesterone (30 mg daily for 6 weeks)
Number of subjects: 53
Study 17126337 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 53
Study 15828052 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 398
Study 15828052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei
Number of subjects: 398
Study 15828052 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 398
Study 12665046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 150 mg
Number of subjects: 30
Study 12665046 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 300 mg
Number of subjects: 30
Study 12665046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10193218 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1
Number of subjects: 180
Study 10193218 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms.kg‐1
Number of subjects: 180
Study 10193218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg.kg‐1
Number of subjects: 180
Study 7619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment (dry powder inhalations of either salbutamol 1600 micrograms or ipratropium bromide 160 micrograms daily)
Number of subjects: 83
Study 7619569 — intervention group
Group type: COMPARATOR
Intervention: On demand treatment (only during exacerbations or periods of dyspnoea)
Number of subjects: 83
Study 7619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 83
Study 7619569 — intervention group
Group type: COMPARATOR
Intervention: On demand treatment
Number of subjects: 83
Study 7619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 83
Study 7619569 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 83
Study 1518167 — intervention group
Group type: EXPERIMENTAL
Intervention: Form A (16 questions)
Number of subjects: 114
Study 1518167 — intervention group
Group type: EXPERIMENTAL
Intervention: Form B (39 questions)
Number of subjects: 114
Study 1518167 — intervention group
Group type: COMPARATOR
Intervention: Cancer patients
Number of subjects: 114
Study 1518167 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-malignant disease patients
Number of subjects: 114
Study 6391134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol treatment
Number of subjects: 144
Study 6391134 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 144
Study 30797381 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT
Number of subjects: 439
Study 30797381 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SBIRT
Number of subjects: 439
Study 30797381 — intervention group
Group type: COMPARATOR
Intervention: SBIRT and e‐SBIRT
Number of subjects: 439
Study 29316143 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 15
Study 29316143 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 15
Study 27021514 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Number of subjects: 35
Study 27021514 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 35
Study 25237669 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-mm implant combined with maxillary sinus floor elevation surgery
Number of subjects: 41
Study 25237669 — intervention group
Group type: COMPARATOR
Intervention: 6-mm implant without any grafting
Number of subjects: 41
Study 22945604 — intervention group
Group type: EXPERIMENTAL
Intervention: High CGA concentration (4525 μmol)
Number of subjects: 0
Study 22945604 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium CGA concentration (2219 μmol)
Number of subjects: 0
Study 22945604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CGA concentration (1053 μmol)
Number of subjects: 0
Study 19951722 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Up Tilt (HUT)
Number of subjects: 16
Study 19951722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic (MA)
Number of subjects: 16
Study 19951722 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic + Head Up Tilt (MA+HUT)
Number of subjects: 16
Study 18191521 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-switch group received liposomal AmB after randomisation
Number of subjects: 32
Study 18191521 — intervention group
Group type: COMPARATOR
Intervention: Late-switch group received liposomal AmB only when sCr increase was >=100% or sCr reached 170mumol/L
Number of subjects: 32
Study 15812080 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin-radiotherapy (CRT)
Number of subjects: 350
Study 15812080 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 350
Study 12775888 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 48
Study 10635419 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 100
Study 10635419 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (625 mg thrice daily for 10 days)
Number of subjects: 100
Study 10635419 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 100
Study 10635419 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 100
Study 7926531 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-osmolality, nonionic contrast agent (Omnipaque 300; iohexol, 672 mOsm/kg H2O)
Number of subjects: 690
Study 7926531 — intervention group
Group type: COMPARATOR
Intervention: High-osmolality, ionic contrast agent (Hypaque 50%; diatrizoate sodium, 1515 mOsm/kg H20)
Number of subjects: 690
Study 2684502 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 795256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (0.8 g daily)
Number of subjects: 12
Study 795256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30790446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment for 6 months
Number of subjects: 66
Study 30790446 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 66
Study 28641582 — intervention group
Group type: EXPERIMENTAL
Intervention: IV levetiracetam infusion (40 mg/kg over 5 min)
Number of subjects: 200
Study 28641582 — intervention group
Group type: COMPARATOR
Intervention: IV phenytoin infusion (20 mg/kg over 20 min)
Number of subjects: 200
Study 25801501 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) 50 mg
Number of subjects: 30
Study 25801501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23906656 — intervention group
Group type: EXPERIMENTAL
Intervention: CP+BEV→BEV
Number of subjects: 0
Study 23906656 — intervention group
Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 0
Study 21425181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine transfusions (IUT) through the intrahepatic portion of the umbilical vein (IHV) or at the placental cord insertion (PCI)
Number of subjects: 25
Study 18503138 — intervention group
Group type: EXPERIMENTAL
Intervention: Octostim nasal spray (300 mug)
Number of subjects: 17
Study 18503138 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 17
Study 17027358 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (100 microg) administered to all individuals, followed by retesting of hormone levels after 4 hours.
Number of subjects: 33
Study 17027358 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration for patients with beta-thalassemia and low T levels.
Number of subjects: 33
Study 17027358 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 33
Study 12551795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold knife
Number of subjects: 110
Study 12551795 — intervention group
Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 110
Study 12551795 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser
Number of subjects: 110
Study 10957698 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 120
Study 10957698 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 120
Study 10957698 — intervention group
Group type: COMPARATOR
Intervention: Amputation
Number of subjects: 120
Study 8838438 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Number of subjects: 0
Study 8838438 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide oxide with cotrimoxazole (960 mg, twice daily for 24 h before and 48 h after administration)
Number of subjects: 0
Study 8254650 — intervention group
Group type: EXPERIMENTAL
Intervention: Harassment condition
Number of subjects: 94
Study 8254650 — intervention group
Group type: COMPARATOR
Intervention: Social Evaluation condition
Number of subjects: 94
Study 2938194 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ipratropium combined with 1.25 mg, 2.5 mg or 5.0 mg fenoterol
Number of subjects: 10
Study 2938194 — intervention group
Group type: COMPARATOR
Intervention: 5.0 mg salbutamol
Number of subjects: 10
Study 2938194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined preparations (ipratropium and fenoterol)
Number of subjects: 10
Study 2938194 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 10
Study 28884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for weight loss
Number of subjects: 91
Study 28884881 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study 28884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups
Number of subjects: 91
Study 28884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 91
Study 27689549 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation via cathodal tDCS over the cM1 combined with 10 Hz rTMS over the iM1
Number of subjects: 20
Study 27689549 — intervention group
Group type: COMPARATOR
Intervention: Other treatment conditions
Number of subjects: 20
Study 23686640 — intervention group
Group type: EXPERIMENTAL
Intervention: GSD (oral glucose spray) - 10 puffs delivering 50 mg of glucose per puff
Number of subjects: 56
Study 23686640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GSD)
Number of subjects: 56
Study 22561965 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 145
Study 22561965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 20440028 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometers (ACC)
Number of subjects: 90
Study 20440028 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC cut‐point ranges
Number of subjects: 90
Study 20440028 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC estimates of absolute PAI
Number of subjects: 90
Study 20440028 — intervention group
Group type: EXPERIMENTAL
Intervention: ACC output expressed in relative vs. absolute terms
Number of subjects: 90
Study 19099974 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable Angina (UA) group
Number of subjects: 60
Study 19099974 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Myocardial Infarction (AMI) group
Number of subjects: 60
Study 19099974 — intervention group
Group type: COMPARATOR
Intervention: Stable Angina (SA) group
Number of subjects: 60
Study 19099974 — intervention group
Group type: COMPARATOR
Intervention: Chest Pain Control (CPS) group
Number of subjects: 60
Study 19099974 — intervention group
Group type: COMPARATOR
Intervention: Normal Control group
Number of subjects: 60
Study 16463697 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cycling exercise test performed after blood donation
Number of subjects: 13
Study 16463697 — intervention group
Group type: COMPARATOR
Intervention: Incremental cycling exercise test performed before blood donation (control study)
Number of subjects: 13
Study 12185425 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min spontaneous breathing trial (SBT) with pressure support ventilation (PSV) at 7 cmH(2)O
Number of subjects: 98
Study 12185425 — intervention group
Group type: EXPERIMENTAL
Intervention: 120-min spontaneous breathing trial (SBT) with pressure support ventilation (PSV) at 7 cmH(2)O
Number of subjects: 98
Study 12185425 — intervention group
Group type: COMPARATOR
Intervention: Comparison of reintubated patients
Number of subjects: 98
Study 12185425 — intervention group
Group type: COMPARATOR
Intervention: ICU mortality
Number of subjects: 98
Study 12185425 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mortality
Number of subjects: 98
Study 12185425 — intervention group
Group type: COMPARATOR
Intervention: Length of ICU stay
Number of subjects: 98
Study 12185425 — intervention group
Group type: COMPARATOR
Intervention: In-hospital length of stay
Number of subjects: 98
Study 10514116 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 154
Study 10514116 — intervention group
Group type: COMPARATOR
Intervention: No Endoscopy
Number of subjects: 154
Study 7815582 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound following papaverine stimulation
Number of subjects: 22
Study 7815582 — intervention group
Group type: COMPARATOR
Intervention: Color duplex ultrasound
Number of subjects: 22
Study 2020763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimorazole (NIM)
Number of subjects: 442
Study 2020763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 6757940 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 14
Study 6757940 — intervention group
Group type: COMPARATOR
Intervention: Sham plasma exchange
Number of subjects: 14
Study 30007557 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1765
Study 30007557 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomization AF
Number of subjects: 1765
Study 30007557 — intervention group
Group type: COMPARATOR
Intervention: No known AF / History of AF without AF at enrollment / AF found on ECG at enrollment
Number of subjects: 1765
Study 26981935 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention comprising professional education, informatics, and financial incentives for practices to review patients' charts.
Number of subjects: 33334
Study 24549255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract (HSE)
Number of subjects: 36
Study 24549255 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study 21350049 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory discrimination training (n = 25)
Number of subjects: 50
Study 21350049 — intervention group
Group type: COMPARATOR
Intervention: Repeated exposure to sensory stimuli (n = 25)
Number of subjects: 50
Study 18762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive distractor (verbal judgment of target distance)
Number of subjects: 44
Study 18762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor distractor (additional movement with right or left hand)
Number of subjects: 44
Study 18762972 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 44
Study 17944738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume 5-aminosalicylic acid foam (2 x 1 g/30 mL)
Number of subjects: 330
Study 17944738 — intervention group
Group type: COMPARATOR
Intervention: High-volume 5-aminosalicylic acid foam (2 x 1 g/60 mL)
Number of subjects: 330
Study 15488868 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 15488868 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic dyslipoproteinemia (ADL) subjects
Number of subjects: 0
Study 15488868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 0
Study 11549328 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity exploration activities
Number of subjects: 76
Study 11549328 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment to avoiding roles
Number of subjects: 76
Study 11549328 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging self-definitions for highly desired possible selves
Number of subjects: 76
Study 9884941 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified preparation (13.9‐17.6 GBq 99mTcO4‐)
Number of subjects: 58
Study 9884941 — intervention group
Group type: COMPARATOR
Intervention: Regular preparation (4.4‐8.8 GBq 99mTcO4‐)
Number of subjects: 58
Study 9884941 — intervention group
Group type: EXPERIMENTAL
Intervention: MRPC for QC testing
Number of subjects: 58
Study 9884941 — intervention group
Group type: COMPARATOR
Intervention: ITLC/SG for QC testing
Number of subjects: 58
Study 9884941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 58
Study 7532938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast and local treatment (nasal and tubal)
Number of subjects: 62
Study 7532938 — intervention group
Group type: COMPARATOR
Intervention: Local treatment (control for Group A)
Number of subjects: 62
Study 3061819 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of perindopril once daily
Number of subjects: 40
Study 3061819 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of perindopril once daily
Number of subjects: 40
Study 3061819 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of perindopril once daily
Number of subjects: 40
Study 3061819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30088288 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + RT
Number of subjects: 187
Study 30088288 — intervention group
Group type: EXPERIMENTAL
Intervention: WL
Number of subjects: 187
Study 30088288 — intervention group
Group type: COMPARATOR
Intervention: WL + AT
Number of subjects: 187
Study 26073355 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Rosuvastatin tablet formulation 1
Number of subjects: 24
Study 26073355 — intervention group
Group type: COMPARATOR
Intervention: 40 mg Rosuvastatin tablet formulation 2
Number of subjects: 24
Study 25661510 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS 13.5mg
Number of subjects: 1432
Study 23060530 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 24
Study 23060530 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 24
Study 23060530 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 21040130 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 10
Study 21040130 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodesiccation
Number of subjects: 10
Study 21040130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 10
Study 21040130 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 10
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical reperfusion using primary percutaneous coronary intervention
Number of subjects: 0
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment with fibrinolytics
Number of subjects: 0
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapies including beta-blockers, aspirin (or clopidogrel if aspirin is contraindicated), nitroglycerin, and analgesia
Number of subjects: 0
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel as adjunctive therapy for patients undergoing fibrinolysis
Number of subjects: 0
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin and low-molecular-weight heparin as adjunctives
Number of subjects: 0
Study 18082788 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple new antithrombin agents
Number of subjects: 0
Study 16412156 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer program used before doctor visit
Number of subjects: 53
Study 12817175 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg (DBPC trials)
Number of subjects: 860